Publication: Síntesis y caracterización de nanofibras
poliméricas como sistema de liberación de
antineoplásicos en un modelo in vitro de
glioblastoma
Loading...
Author
Badía Hernández, Pedro Valentín
Journal Title
Journal ISSN
Volume Title
Date
Citation
Conference
Publisher
Universidad Miguel Hernández de Elche
Abstract
El glioblastoma es un tipo de glioma de baja incidencia, pero de alta tasa de mortalidad
debido a su malignidad. Los tratamientos actuales para el glioblastoma se centran en la cirugía
seguida por quimioterapia; sin embargo, la administración sistémica de antineoplásicos daña
tejidos y células sanas del resto del cuerpo, por lo que se investiga su aplicación local y su
liberación controlada. Su encapsulación en nanofibras poliméricas puede permitir una
liberación controlada y aumentar su biodisponibilidad. En este trabajo se sintetizaron
nanofibras de poli(metil vinil éter-alt-ácido maleico) (PMVEMA) como sistema de liberación de
temozolomida (TMZ), carmustina (BCNU) y doxorrubicina (DOX). Su caracterización
morfológica por microscopia electrónica (FESEM) mostró un diámetro variable entre los 300 y
400 nm al incorporar cada fármaco a una concentración 1:20 (% p/p) respecto al polímero.
Además, se confirmó la encapsulación de TMZ y DOX en las nanofibras a través de
espectroscopía de infrarrojo y microscopia confocal, respectivamente. Finalmente, se
comprobó su efecto antineoplásico con el ensayo de viabilidad celular MTT en líneas celulares
de glioblastoma, mostrando disminución en la viabilidad celular dependiente de la dosis a
concentraciones crecientes del fármaco.
Glioblastoma is a type of glioma with low incidence but high mortality rate due to its malignancy. Current treatments for glioblastoma focus on surgery followed by chemotherapy; however, systemic administration of antineoplastics damages healthy tissues and cells in the rest of the body, so their local application and controlled release is being investigated. Their encapsulation in polymeric nanofibers may allow their controlled release and increase their bioavailability. In this work, poly(methyl vinyl ether-alt-maleic acid) (PMVEMA) nanofibers were synthesized as a delivery system for temozolomide (TMZ), carmustine (BCNU) and doxorubicin (DOX). Their morphological characterization by electron microscopy (FESEM) showed a variable diameter between 300 and 400 nm when incorporating each drug at a 1:20 concentration (% w/w) with respect to the polymer. In addition, the encapsulation of TMZ and DOX in the nanofibers was confirmed by infrared spectroscopy and confocal microscopy, respectively. Finally, their antineoplastic effect was assessed with the MTT cell proliferation assay in glioblastoma cell lines, showing a dose-dependent decrease in cell viability at increasing concentrations of the drug.
Glioblastoma is a type of glioma with low incidence but high mortality rate due to its malignancy. Current treatments for glioblastoma focus on surgery followed by chemotherapy; however, systemic administration of antineoplastics damages healthy tissues and cells in the rest of the body, so their local application and controlled release is being investigated. Their encapsulation in polymeric nanofibers may allow their controlled release and increase their bioavailability. In this work, poly(methyl vinyl ether-alt-maleic acid) (PMVEMA) nanofibers were synthesized as a delivery system for temozolomide (TMZ), carmustine (BCNU) and doxorubicin (DOX). Their morphological characterization by electron microscopy (FESEM) showed a variable diameter between 300 and 400 nm when incorporating each drug at a 1:20 concentration (% w/w) with respect to the polymer. In addition, the encapsulation of TMZ and DOX in the nanofibers was confirmed by infrared spectroscopy and confocal microscopy, respectively. Finally, their antineoplastic effect was assessed with the MTT cell proliferation assay in glioblastoma cell lines, showing a dose-dependent decrease in cell viability at increasing concentrations of the drug.
